TY - JOUR
T1 - Dextromethorphan protect the valproic acid induced downregulation of neutrophils in patients with bipolar disorder
AU - Lu, Ru Band
AU - Chang, Yun Hsuan
AU - Lee, Sheng Yu
AU - Wang, Tzu Yun
AU - Cheng, Shu Li
AU - Chen, Po See
AU - Yang, Yen Kuang
AU - Hong, Jau Shyong
AU - Chen, Shiou Lan
N1 - Funding Information:
This work was supported by Taiwan Ministry of Science and Technology (MOST) grants MOST 105-2314-B-006-007-MY2 (to RBL) and MOST 105-2628-B-037-003-MY3 (to SLC). This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Publisher Copyright:
Copyright © 2020, Korean College of Neuropsychopharmacology
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020
Y1 - 2020
N2 - Objective: Valproic acid (VPA) is an anticonvulsant and commonly long term used as a mood stabilizer for patients with mood disorders. However its chronic effects on the hematological changes were noticed and need to be further evaluated. In this study, we evaluated, in Taiwanese Han Chinese patients with bipolar disorders (BD), the chronic effects of VPA or VPA plus dextromethorphan (DM) on the hematological molecules (white blood cell [WBCs], red blood cells [RBCs], hemoglobin, hematocrit, and platelets). Methods: In a 12-week, randomized, double-blind study, we randomly assigned BD patients to one of three groups: VPA plus either placebo (VPA+P, n = 57) or DM (30 mg/day, VPA+DM30, n = 56) or 60 mg/day (VPA+DM60, n = 53). The Young Mania Rating Scale and Hamilton Depression Rating Scale were used to evaluate symptom severity, and the hematological molecules were checked. Results: Paired t test showed that the WBC, neutrophils, platelets and RBCs were significantly lowered after 12 weeks of VPA+P or VPA+DM30 treatment. VPA+DM60 represented the protective effects in the WBCs, neutrophils, and RBCs but not in the platelets. We further calculated the changes of each hematological molecules after 12 weeks treatment. We found that combination use of DM60 significantly improved the decline in neutrophils induced by the long-term VPA treatment. Conclusion: Hematological molecule levels were lower after long-term treatment with VPA. VPA+DM60, which yielded the protective effect in hematological change, especially in the neutrophil counts. Thus, DM might be adjunct therapy for maintaining hematological molecules in VPA treatment.
AB - Objective: Valproic acid (VPA) is an anticonvulsant and commonly long term used as a mood stabilizer for patients with mood disorders. However its chronic effects on the hematological changes were noticed and need to be further evaluated. In this study, we evaluated, in Taiwanese Han Chinese patients with bipolar disorders (BD), the chronic effects of VPA or VPA plus dextromethorphan (DM) on the hematological molecules (white blood cell [WBCs], red blood cells [RBCs], hemoglobin, hematocrit, and platelets). Methods: In a 12-week, randomized, double-blind study, we randomly assigned BD patients to one of three groups: VPA plus either placebo (VPA+P, n = 57) or DM (30 mg/day, VPA+DM30, n = 56) or 60 mg/day (VPA+DM60, n = 53). The Young Mania Rating Scale and Hamilton Depression Rating Scale were used to evaluate symptom severity, and the hematological molecules were checked. Results: Paired t test showed that the WBC, neutrophils, platelets and RBCs were significantly lowered after 12 weeks of VPA+P or VPA+DM30 treatment. VPA+DM60 represented the protective effects in the WBCs, neutrophils, and RBCs but not in the platelets. We further calculated the changes of each hematological molecules after 12 weeks treatment. We found that combination use of DM60 significantly improved the decline in neutrophils induced by the long-term VPA treatment. Conclusion: Hematological molecule levels were lower after long-term treatment with VPA. VPA+DM60, which yielded the protective effect in hematological change, especially in the neutrophil counts. Thus, DM might be adjunct therapy for maintaining hematological molecules in VPA treatment.
KW - Bipolar disorder
KW - Blood platelets
KW - Dextromethorphan
KW - Erythrocytes
KW - Neutrophils
KW - Valproic acid
UR - http://www.scopus.com/inward/record.url?scp=85084486529&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084486529&partnerID=8YFLogxK
U2 - 10.9758/CPN.2020.18.1.145
DO - 10.9758/CPN.2020.18.1.145
M3 - Article
AN - SCOPUS:85084486529
VL - 18
SP - 145
EP - 152
JO - Clinical Psychopharmacology and Neuroscience
JF - Clinical Psychopharmacology and Neuroscience
SN - 1738-1088
IS - 1
ER -